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Abstract
64Cu (Iβ+ = 17%, Iβ− = 39%, IEC = 43%) is an important emerging biomedi-
cal radionuclide that is suitable for labelling a wide range of radiopharmaceuticals
for PET imaging, as well as systemic or local radioimmunotherapy of tumours. Its
positron energy spectrum is comparable with that of 18F, allowing high spatial res-
olution in PET imaging. Its intermediate half-life (12.7 h) permits PET evaluation
of slow biochemical pathways, such as protein and peptide interactions with cellular
targets, and distribution to satellite imaging and therapy centres. The optimum pro-
duction route for radiochemically-pure, carrier-free 64Cu is via the reaction 64Ni(p,n)
at 12→9 MeV followed by anion exchange chromatography. Biomedical applications
follow three principal strategies: (i) direct application of 64Cu as a biological tracer, (ii)
complexing with redox sensitive ligands (e.g. bisthiosemicarbazones) that release 64Cu
upon reduction in hypoxic cells, and (iii) coordination with bifunctional ligands (e.g.
tetraaza macrocycles) that covalently bond to intact antibodies, antibody fragments,
peptides, peptide analogues or shell cross-linked nanoparticles for targeting receptors
expressed by tumours.
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Abbreviations and symbols
α alpha particle, decay mode, molecular orbital or peptide subunit
β beta decay mode, molecular orbital or peptide subunit
γ gamma quantum
νe electron neutrino
νe electron anti-neutrino
τ lifetime
A atomic mass number
Ab antibody
ALARA as low as reasonably achievable
ATSM diacetyl-bis(N4-methlythiosemicarbazone)
B binding energy
BBN bombesin
Bq Bequerel
BTS bis(thiosemicarbazone)
c speed of light
conc. concentrated
COSTIS compact solid target irradiation system
d deuteron, or atomic orbital
d diammeter
D symmetry group
DG deoxy-glucose
DOTA 1,4,7,10-tetraazacyclododecane-N,N’,N”,N”’ -tetraacetic acid
E energy
2
e− electron
e+ positron
EC electron capture
ED effective dose
EOB end of bombardment
EOIB end of instantaneous bombardment (decay-uncorrected EOB)
EDTA ethylenediaminetetraacetate
eV electron volt
FDG fluoro-2-deoxy-2-d-glucose
ft comparative half-life of β-decay
FMISO fluoromisonidazole
FR folate receptor
FWHM full-width half-maximum
GRP gastrin-releasing peptide
HIV human immunodeficiency virus
HOMO highest occupied molecular orbital
I intensity
IAEA International Atomic Energy Agency
Kd distribution factor
LET linear energy transfer
LUMO lowest unoccupied molecular orbital
m mass
mAb monoclonal antibody
mRNA messenger ribonucleic acid
n neutron
N neutron number
OC octreotide
p proton
P probability
PEG poly(ethylene glycol)
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PET positron emission tomography
pH pondus hydrogenii (potential of hydrogen)
PNA peptide nucleic acid
pKa inverse logarithm of the acid dissociation constant
PTSM pyruvaldehyde-bis(N4-methlythiosemicarbazone)
Q atomic energy change for a nuclear process
R diantipyrylpropylmethane
RES reticuloendothelial system
RGD arginineglycineaspartic acid
RIT radioimmunotherapy
SA specific activity
SCK shell cross-linked nanoparticle
T kinetic energy
t1/2 half-life
Tb biological half-life
TETA triethylenetetraamine
TLC thin layer chromatography
Z atomic number
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Chapter 1
Introduction
Molecular imaging and radiotherapy using radionuclides is a rapidly expanding field
of medicine and medical research [1]. [18F]FDG-PET has long been used to assess
glucose consumption of malignant cells, but problems with cell proliferation and the
need for more specific oncologic markers have led to the development of new tracers
[2]. The increasing amount of clinically relevant information obtained by PET has
also generated a demand for new routes for the widespread and cost-effective use of
positron-emitting radiopharmaceuticals and for more versatile positron emitters [3, 4].
New PET ligands for clinical use will not be restricted to just 18F-labelled ligands,
as novel molecules are emerging labelled with non-conventional positron emitters [5].
Many of the useful radionuclides are metallic, and so inorganic chemistry (including
organometallic chemistry) is playing an increasingly key role in the development of
radiopharmaceutics [1].
This dissertation reviews the recent scientific literature on the production, ligands
and biomedical applications of 64Cu, a radionuclide that decays by three modes: β−,
β+ and electron capture. This radioisotope of copper is regarded by its proponents, and
more objectively by the IAEA, as one of the most important emerging therapeutic ra-
dionuclides that permits a combination of therapy and PET [6]. 64Cu is a radionuclide
suitable for labelling a wide range of radiopharmaceuticals for PET imaging, as well as
systemic or local radioimmunotherapy of tumours [7]. It is also in demand as a candi-
date radionuclide for immuno-PET, where quantitative imaging before or concomitant
with radioimmunotherapy (RIT) can improve confirmation of tumour targeting and
especially the assessment of radiation dose delivery to both tumour and normal tis-
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sues [8, 9]. Very recently, 64Cu has shown potential in the novel use of PET in drug
development.
An amenable chemistry and biochemistry, and good potential for radionuclide pro-
duction and supply, means that copper radionuclides offer to nuclear-medicine prac-
titioners a range of services similar to the radionuclides of iodine [10]. Copper co-
ordination chemistry is straighforward and therefore well-suited for the high-turnover
demand at a clinical PET centre [11].
One of the most widely recognised advantages of PET is its use of positron-emitting
bio-radionuclides (11C, 13N, 15O) for the investigation of biological processes. Thus
the difficulties of designing non-endogenous radiotracers that reliably mimic natural
substrates can, in some cases, be avoided. The half-lives of these bio-radionuclides
are very short (20, 10 and 2 min, respectively), which is an advantage for imaging
humans since large amounts of radioactivity can be administered for good counting
rates initially while maintaining a fairly low total absorbed radiation dose [3]. However,
there are two major drawbacks.
Firstly, the very short half-lives of these PET bio-radionuclides preclude their use
for the study of prolonged biological processes, e.g. protein and peptide interactions
with their cellular targets [12, 13]. For instance, advances in the use of monoclonal
antibodies and related radioimmunotherapy favour the use of long-lived radioisotopes
in tumour diagnosis and therapy. Furthermore, the only feasible means of detecting
accurately receptor sites present in low concentrations is by using very high-affinity
ligands labelled with long-lived isotopes that permit the wash-out phase to be analysed.
In late images of long-lived radiotracers the receptor-bound tracer should dominate the
images, while with shorter-lived isotopes the non-specific binding may be considerable
and must be accounted for [3, 14].
Secondly, the PET bio-radionuclides are too short-lived to be transported long dis-
tances. PET units that routinely use 11C, 13N and 15O must not only invest in a camera
and supporting equipment, but also have access to a cyclotron and radiochemistry fa-
cilities. The capital investments needed on site are therefore heavier than for any other
imaging technique, and can be a reason for the techniques relative inaccessibility. The
positron emitter 18F (t1/2 = 1.8 h) is often used in labelling reactions to generate ana-
logues of compounds in which a C−H of C−OH bond has been replaced with a C−18F
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bond. Synthesis of large quantities of the widely-used tracer [18F]FDG is well validated
and automated for supply of this relatively long-lived tracer to imaging units without
their own tracer production facility. By using other, longer-lived radionuclides that can
be transported greater distances from a host accelerator facility or by using generator-
produced isotopes, the complexities associated with in-house radionuclide productions
might be avoided, capital expenses reduced and personnel costs minimised. Use of
alternative radionuclides presents a number of interesting possibilities not currently
pursued by most conventional PET units [3].
The following chapters evaluate the 64Cu production and labelling methods perti-
nent to biomedicine, and illustrate some of the applications reported recently in the
literature. The remaining sections of this introductory chapter examine the radioactive
decay properties of 64Cu due to their important implications for imaging and dosimetry
in biological systems [15].
1.1 Decay properties of 64Cu
Production of 64Cu by nuclear reaction yields the nucleus in one of 172 known excited
levels with a maximum excitation energy of ≈ 8170 keV [16]. De-excition proceeds
rapidly by cascading prompt γ-emission with half-lives of typically ≤ 21 ps [16]. The
1594 keV level though has a longer lifetime, τ = 29.5 ns, due to weak branching [17].
The ground state of the odd Z-odd N nucleus is still unstable to β decay to either of
its neighboring even Z-even N isobars (Figure 1.1). The half-life of 64Cu is 12.7 h.1
The comparative half-lives, or ft values, are such that all three β decay modes are
classified as allowed [19]. Branching of the competing modes of its β− and β+ decays
and electron capture is illustrated in Figure 1.2.
Electron capture (EC, I = 43.7%) from the K or L shells of the copper atom induces
the nucleon n→p conversion, monoenergetic νe emissions, and branching to either the
1345.77 keV-level (I = 0.473%) or the ground state (I = 43.2%) of 64Ni. The atomic
energy change, i.e. Q-value, for the 64Cu→64Ni transition is 1675.10 keV. The excited
level of 64Ni decays rapidly, t1/2 = 0.88 ps, by emission of a single 1345.77 keV γ-ray.
Filling of the orbital electron vacancy by higher-level electrons produces characteristic
1Unless otherwise cited, data pertaining to radioactive decay is from [18].
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Figure 1.1: Mass-chain decay scheme for isobars A = 64. 64Cu appears on a ridge near
the middle of this valley of β stability. The semi-empirical mass equation indicates
that the theoretical bottom of the valley is located at Z = 28.4, i.e. between Ni and
Cu [20]. Figure modified from [21].
Figure 1.2: Decay scheme of 64Cu. Although the decay energetics are known precisely,
there is still disagreement in the literature regarding branching ratios [22, 23]. Figure
modified from [24].
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Table 1.1: Particle and electromagnetic emissions from the radioactive decay of 64Cu,
their mean and maximum energies and intensities. X-rays of I < 1% are omitted for
clarity. Neutrino energies for are EC calculated assuming K capture and QEC= Eνe−Bi
[25], where the K-shell binding energy for nickel is BK = 8.333 keV [26]. Data taken
directly or calculated from [18,27].
Mode Emission E / keV Emax / keV Intensity / %
EC νe 321.00 0.473
νe 1666.77 43.2
γ 1345.77 0.473
X Ni Kα2 7.461 4.72
X Ni Kα1 7.478 9.3
X Ni Kβ1,3 8.265 1.68
Auger Ni L 0.84 57.4
Auger Ni K 6.54 22.39
β+ νe 653.10 17.4
e+ 278.21 653.10 17.4
β− νe 578.7 39.0
e− 190.2 578.7 39.0
X-rays and Auger electron emissions. Table 1.1 lists the emissions resulting from EC
and other decay modes of 64Cu.
Since the energy difference between 64Cu and 64Ni exceeds 1022 keV then decay by
β+ emission to nickel is also permitted. Its intensity is 17.4%, and like EC it involves the
nucleonic n→p conversion and νe emission. In addition to the formation of a positron,
the expulsion of a orbital electron is subsequently required so that daughter nickel atom
attains neutrality [20, 25]. Thus the positron end-point energy is two electron masses
smaller than the total transition energy, i.e. (Te+)max = QEC−2mec2 = 653.10 keV.
The mean positron kinetic energy is however 278.21 keV.
Slightly less energetic, but still competitive at I = 39.0%, is β− decay to the ground
state of 64Zn. The Qβ− = 578.7 keV is shared between the emitted electron and electron
antineutrino. The mean electron kinetic energy is 190.2 keV.
The shapes of positron and electron energy spectra for 64Cu are dissimilar (Fig-
ure 1.3). Semiclassically, the shapes of the energy distributions can be interpreted
as Coulomb repulsion of e+ by the nucleus, giving fewer low-energy positrons, and a
Coulomb attraction of e−, giving more low-energy electrons [28]. In quantum mechan-
ical terms, it is the nuclear Coulomb field that distorts the e± wave functions, with the
magnitude of the distortion more significant at lower energies [19,28,29].
The β− and β+ decays of 64Cu are also accompanied by ionisation (or excitation) of
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Figure 1.3: Kinetic energy spectra of electrons (left) and positrons (right) emitted in
the decay of 64Cu. Figure from [28].
the electron cortege of the daughter nickel or zinc atoms, a higher order process com-
monly referred to as internal ionization [30]. The two basic mechanisms contributing to
such inner-shell electron ionisation are (i) the shake-off mechanism which is attributed
to the sudden change in nuclear charge, and (ii) the direct collision mechanism (also
known as final-state interaction) where an orbital electron is Coulomb scattered by the
emerging β particle [31]. Since the Qβ± for
64Cu far exceed K-shell binding energies
for nickel and zinc, then the shake-off mechanism is predominant [31–34]. Internal
ionisation for 64Cu has been quantified experimentally, and expressed as the number
of K-shell vacancies per emitted e±: PK(β−) = 0.0012, PK(β+) = 0.0014 [35,36]. Thus
inner-shell ionisation infrequently accompanies nuclear β decay, and the intensities
of X-rays following internal ionisation are relatively minor when compared to those
resulting from EC.
1.2 Imaging with 64Cu
Even though PET cameras have some energy discrimination that reject photons out-
side a select energy window, interference between 511 keV annihilation photons and
other photons may still occur [3]. The 1346 keV γ-emission from 64Cu EC decay is
far outside the annihilation energy window and has an intensity 37 times lower than
that of positron emission, so does not contribute significantly to additional random
coincidences or pile-up problems in detector electronics.
High-resolution PET cameras have been developed for imaging of small animals and
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in clinical neurology, e.g. µPET or high-resolution research tomographs [37]. Because
small animal PET is immediately extrapolatable to the clinic, it offers the possibility for
laboratory advances to be translated rapidly to clinical practice [38]. This technology is
increasing in popularity – and increasingly with 64Cu-labelled agents – in drug discovery
and preclinical evaluation of oncologic imaging [39, 40]. Its efficacy largely depends
on the quality of image resolution than can be attained. The unavoidable physical
limits of spatial resolution are due mainly to positron range, annihilation photon non-
collinearity2 and detector element width [41]. Intrinsic resolution impairment is a
function of the characteristic positron energy, and can be approximated for positron
emission in tissue using the monoexponential equation [3]:
intrinsic loss of spatial resolution [mm] = 1.18(Eβ+max[MeV])
1.14 (1.1)
Such a simple expression neglects differences in energy spectral profiles for radionu-
clides with similar positron end-point energies but dissimilar nuclear Coloumb fields.
Figure 1.4 plots the simplified resolution losses for both conventional and alternative
PET radionuclides. To a first approximation using Equation (1.1), 64Cu has a com-
paratively low resolution loss of 0.73 mm, very similar to the 0.7 mm value for ideal
PET radionuclide 18F (due to similar positron spectra, and thus similar ranges and
annihilation photon non-collinearities) and better than all three of the conventional
PET bio-radionuclides (11C, 13N, 15O).
A more sophisticated analysis of image resolution for different positron emitter
used electron transport calculations. The convolution of functions representing photon
noncollinearity, detector response and positron range kernel (Figure 1.5) confirm that
in µPET the detector size is still the limiting factor in image resolution for radionuclides
emitting low-energy positrons such as 18F and 64Cu. The dominant factor for the other
radionuclides is positron range [42].
For 18F, scanners with diameters ≤ 20 cm (typical for animal imaging systems)
spatial resolution for will attain its intrinsic limit only when detector element widths
are below 1 mm. For an 80 cm diameter system (typical for human imaging) resolution
improvement saturates (at 2.0 mm FWHM) below a 2 mm crystal width since the
2Because the centre of mass of the positron and atomic electron system is not always at rest at
their annihilation, in order to conserve energy and momentum, the annihilation photons created are
not always 180 deg apart [41].
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Figure 1.4: Intrinsic spatial resolution losses for conventional and novel PET radionu-
clides. Plot based on data from [3,18] and Equation (1.1). Energies are weighted with
relative yields for positrons emitted with different energies [3].
Figure 1.5: (a,b) Range convolution kernels for 18F and selected nonconventional
positron emitters. Figure from [42].
response is dominated by photon non-collinearity [41].
1.3 64Cu dosimetry
A premise of clinical PET imaging is that sufficiently large amounts of a positron emit-
ter can be administered to maintain high signal-to-noise and that repeated studies can
be performed without unacceptably high radiation doses. Doses delivered by positrons
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Table 1.2: Comparison of effective dose constants and effective doses (ED) at biolog-
ical half-lives (Tb) of 1, 10 and 100 h for a conventional PET radionuclide (
18F) and
for 64Cu. Values are calculated using MIRDOSE software [43] assuming complete uni-
form distribution of the radionuclides in an adult standard man [3]. Estimating doses
to individual organs in a real clinical setting is notoriously difficult due nonuniform
distributions of radioactivity in a tumour [44].
Radionuclide ED constant ED ED ED
µSv MBq−1h−1 µSv MBq−1 µSv MBq−1 µSv MBq−1
Tb = 1 h Tb = 10 h Tb = 100 h
18F 5.37 5.00 12 13.9
64Cu 1.59 2.12 12.8 25.8
(aside from annihilation radiation) are as large as those delivered by electrons of the
same energy. When using a radionuclide that is longer-lived than conventional PET ra-
dionuclides, dosimetry considerations may therefore become a limiting factor in clinical
PET [3]. Table 1.2 compares the doses of 18F and 64Cu at various biological half-lives.
The actual doses in practice may also differ due to different biological behaviour and
alternative tissue concentrations [3]. But the low Iβ+ and long physical half-life of
64Cu indicate that caution is recommended for exclusively imaging applications when
using 64Cu-radiopharmaceuticals with long biological half-lives due to the potentially
high doses. If the clinical imaging application necessitates using a copper-based ra-
diopharmaceutical, then it is also prudent to consider labelling instead with positron
emitters 60−62Cu. Unfortunately, these isotopes emit positrons with significantly higher
energies, and so would be more suited to clinical PET where spatial resolution is less
critical than in µPET.
The unusual combination of emissions from low-energy e− and e+ and Auger elec-
trons from 64Cu may be advantageous for its cytotoxic potential in small tumours. Its
low-energy e± (mean ranges 0.4–0.9 mm) are best suited for localization on the cellular
surfaces or cytoplasm of small tumours (d ' 1 − 2 mm) [4, 45]. The Auger electrons
have a mean range of 6 µm due to their low energy, and therefore are only of use in
therapy if the source is attached to, or very close to, the cell nucleus. Auger elec-
trons have therapeutic potential in oncology due to their high level of cytotoxicity and
short-range biological effectiveness [46]. Auger electron emission produces an array of
reactive radicals (e.g. OH · , H · and e−aq) similar to α-emission, which is regarded as
the classical form of high LET.
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Chapter 2
Production of carrier-free 64Cu
64Cu is a synthetic radionuclide that cannot be conveniently produced by decay of
isobars, and so must be produced by ion or neutron irradiation. The importance
of production methods reflects essential qualities demanded in radiopharmacy such as
radionuclide and chemical purities and specific activity (SA). The latter is more critical,
for example, in receptor binding agents such as monoclonal antibodies (mAbs) [45], and
has a theoretical maximum of 1.43 ·1017 Bq g−1 Cu. Radioactive impurities have a dual
detrimental effect: firstly, they adversely affect imaging resolution and secondly, cause
enhanced radiation dose to the patient [47]. Fortunately 64Cu has only extremely short-
lived excited nuclear states, so there is no problem with producing unwanted isomeric
impurities.
In the majority of radionuclide production cases the proton-induced reactions are
the most productive processes. However, deuteron-induced reactions can compete in
terms of productivity or target material cost [48]. Production via neutron bombard-
ment in reactors yields typically radionuclides with low SA, due to competition with
(n,γ) products that β-decay to other isotopes of the desired element. Furthermore,
access to reactors is limited compared to accelerators. The reduction in the number of
reactors will probably continue over the next decade [49].
Experimental nuclear reaction database EXFOR [50] lists cross-section values for 66
different reaction channels yielding 64Cu. The channels are composed of four nuclear
reaction types. First, compound nucleus reactions proceed by near or near-central
collisions where projectiles and targets fuse together, then through successive nucleonic
collisions the reaction energies are shared among many nucleons. Compound nuclei
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Table 2.1: Nuclear reactions yielding carrier-free 64Cu. Q-values and reaction thresh-
old energies (Ethr) are from [51]. Energy ranges are restricted to strictly carrier-free
production. Yields are maximum empirical yield values or are integrated over optimum
energy range using thin target cross-section values.
Reaction Q-value Ethr E range Yield
[MeV] [MeV] [MeV] [MBq/µAh]
64Ni(p,n) −2.46 2.50 12→9 ≤496
64Ni(d,2n) −4.68 4.83 19→15 389
64Zn(d,2p) −2.02 2.08 13→7 4
66Zn(d,α) 7.42 0 13→7 ≥7
68Zn(p,αn) −7.79 7.91 25→10 67
64Zn(n,p) 0.20 0 ≤15
can exist in excited states for a long time (10−18 − 1016 s) until, by chance, a single
nucleon or group of nucleons acquire enough energy to escape. Second, direct reactions
occur when projectiles interact primarily in the surface of target nuclei. Energy and
material transfers are small, and the timescale of direct reactions is rapid (∼ 10−22
s) [29]. Compound nucleus and direct reactions yielding 64Cu are mostly between light
projectiles and A = 61–71 targets. The other two types of reactions are less common:
fission and spallation (boiling off of neutrons) reactions induced by high-energy proton
bombardment on massive nuclei.
The probabilities of the above reactions are expressed as cross-section values as a
function of projectile energy. Promotion of the channels most suited to radiopharmacy
has varied with the purity and quantity demands of the end user, and with investment
in isotopically enriched target materials and low-energy cyclotrons. Of the 66 channels,
only six that are open to reactors and low-energy cyclotrons have proven to yield 64Cu
in a carrier-free form (Table 2.1). Figure 2.1 shows the relative positions of target and
product nuclides involved in the reactions. The reaction channels will be discussed here
with regard to yields, targetry and product separation. Their excitation functions are
plotted in Figure 2.2.
Target economics favour naturally abundant targets, since isotopic enrichment by
electromagnetic separation greatly increases material costs [52]. Although co-produced,
non-isotopic impurities can be removed by chemical separation, the level of isotopic
impurities can be suppressed only using enriched isotopes as target materials and/or
careful selection of the particle energy range effective in the target [47]. Many groups
have tried to produce 64Cu from targets of natural elemental composition, but have
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Figure 2.1: Chart of the nuclides involved in the compound nucleus and direct reactions
yielding carrier-free 64Cu. Figure modified from [21].
yielded a smorgasbord of impurities making efficient separation of carrier-free 64Cu
unfeasible. It would appear that co-production of other radiochemical impurities is
almost unavoidable, but to prevent radioisotopic impurities it is imperative to use a
highly enriched monoisotopic target.
2.1 Ion irradiation of nickel
2.1.1 64Ni(p,n)64Cu
The 64Ni(p,n) reaction route is justifiably popular because its entrance channel is acces-
sible at low energies (Ethr = 2.50 MeV) and it has large cross sections over the energy
range typical of small biomedical cyclotrons. This pathway is used extensively and has
seen significant development in yields by using thicker targets and more intense proton
beams. Early pioneering studies yielded a credible 185 MBq/µAh [12]. The highest
recorded yield is 496 MBq/µAh from a 3 h bombardment with 40 µA beam of 12.5 MeV
protons producing 46 GBq at EOB, which is sufficient to provide 64Cu-pharmaceuticals
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Figure 2.2: Excitation functions for reactions yielding isotopically pure 64Cu. Upper
graph: Spline fits to empirical cross-section data currently most accurate [53–57]. Lower
graph: Excitation function for 64Zn(n,p). Points are experimental data, all available
from EXFOR ( [50]), and best fit curve is known as the Activation library curve
from [58]. Figure from [58].
for at least 3 days of PET studies [11].
Some isotopic impurity (< 3%) is co-produced via the reaction 64Ni(p,α)61Co.
However, due to its short half-life (1.6 h) 61Co would not introduce much distur-
bance [53]. The target material will contain small quantities isotopes of nickel other
than 64Ni, leading to production of radiochemical impurities such as 57Ni, 55−58Co and
60Cu [59]. Hence the desire for a highly-enriched target. The impurity contribution
from 60Ni(p,n)60Cu can be minimised by irradiating below 12 MeV [50], or more con-
veniently it can aged out (t1/2 = 24 min). The only notable radiochemical impurity
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detected 3 h after EOB is 55Co (t1/2 = 18.2 h). However, its low yield of 1% relative
to 64Cu means that the radiochemical purity of 64Cu is ≥ 99% at 3 h after EOB [60].
Specific activities have been reported to range from 2.9 ·1015 to 1.2 ·1016 Bq g−1 [12,60].
2.1.2 64Ni(d,2n)64Cu
The 64Ni(d,2n) pathway is another very high-yielding production route. The excitation
function looks attractive with a maximum cross section of 800 mb at 16 MeV [6,
54]. Calculations from the excitation function over the energy window 19→15 MeV
suggest possible yields of 389 MBq/µAh [54]. However, significant uncertainties in the
calculations of actual yields remain due to extrapolations from results of experiments
on natNi [6]. 64Cu is the predominant radionuclide produced and a large amount of the
short-lived 65Ni (t1/2 = 2.5 h) is also produced by the
64Ni(d,p) reaction. Also present
at EOB are other copper, cobalt and nickel radionuclides yielded from the isotopic
impurities in the < 100% enriched 64Ni target material [54]. Although the 64Ni(d,2n)
pathway gives very high yields, the energy and intensity of commonly available deuteron
beams are generally low. Thus this reaction has hitherto not found any practical
application [56].
2.2 Ion irradiation of zinc
The deuteron irradiation of natZn continues to attract interest for 64Cu production
due to the ready availability of cheaper natZn as a target material [48, 61]. How-
ever, there are large discrepancies in the excitation functions for specific reactions
from natZn(d,x)64Cu [56]. Deuteron irradiation of natZn yields 64Cu from several differ-
ent reactions: 64Zn(d,2p), 66Zn(d,α), 67Zn(d,αn), 67Zn(d,3He2n) (Ethr = 21 MeV) and
68Zn(d,α2n) (Ethr = 10.3 MeV) [62]. The decay-uncorrected, experimental thick-target
yield for natZn(d,x)64Cu at EOIB is 31 MBq/µAh. A 25.4 h (2·t1/2) 19 MeV d irradi-
ation at 100 µA on thick natZn could theoretically produce 42.3 GBq at EOB. After
radiochemical separation the yield would be 3 GBq. After a proper cooling time to al-
low 61Cu to decay out (EOIB yield 3.3 times higher than that of 64Cu), it is possible to
radiochemically separate 64Cu with a radionuclidic purity suitable for high-resolution
PET imaging [7].
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Unfortunately there is also significant co-production of several other radionuclides.
In addition to 61,64Cu, irradiating with 19 MeV d yields 66,67Ga, 65,69mZn and 57,58Co,
and increasing the d energy to a more productive 30 MeV adds 62Zn and 67Cu to the
list of impurities [7, 62]. There is no experimental evidence of 67Cu produced with 19
MeV d on natZn, even when it is energetically allowed from 67,68,70Zn: the low natural
abundance of 70Zn and large Coulomb barriers for reactions from 67,68Zn hinder pro-
duction of 67Cu [7]. The most significant radioactive impurity is 66Ga (t1/2 = 9.5 h)
with a thick-target yield from 19 MeV d 4.5 times higher than that of 64Cu [62]. In
principle such impurities can be removed by radiochemical separation methods. How-
ever, there are two reasons why this production route is less than attractive. Firstly,
handling of an irradiated natZn target has to be performed in highly radiation-shielded
cells due to the intense, high-energy γ-radiation from 66Ga: Iγ(1038 keV) = 37% and
Iγ(2752 keV) = 23% [27, 63]. Secondly, there are also concerns about the radioactive
waste stream from the radiochemical separation (65Zn and 57Co have half-lives of 244
and 272 d, respectively) [63] that clearly run contrary to ALARA principles in view of
other, cleaner production routes.
2.2.1 64Zn(d,2p)64Cu
The 64Zn(d,2p) pathway has the highest cross sections for carrier-free production of
64Cu via ion irradiation of zinc. Nevertheless, only one cross-section data set has been
reported for an enriched 64Zn target, which showed that a suitable irradiation energy
range would be 13→17 MeV [55]. Production yields have yet to explored. Calculations
from the excitation function suggest a possible yield of 4 MBq/µAh.
2.2.2 66Zn(d,α)64Cu
The 66Zn(d,α) is a potentially important reaction [6,64]. It has a positive Q-value and
subsequently its entrance channel has no inhibiting threshold energy. Its excitation
function increases rapidly until a maximum of 27 mb at approximately 11 MeV, there-
after its yield appears to reach saturation. A suitable energy range for production of
64Cu via this reaction would be Ed = 13→7 MeV [56]. No isotopic impurities have
been detected. The yield is rather low and whether it can compete with 64Ni(p,n) is
still under debate [65].
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2.2.3 68Zn(p,αn)64Cu
High-energy proton irradiation of natZn yields radionuclides of gallium, zinc, cop-
per, nickel, cobalt, vanadium and manganses radionuclides. The cross sections for
natZn(p,x)67Cu are approximately 10% of that for natZn(p,x)64Cu [66]. Thus it is es-
sential to use a highly enriched target.
The 68Zn(p,αn) pathway was investigated earlier for the simultaneous production of
medical radionuclides 62Zn(62Cu), 62,64,67Cu and 67Ga [67,68]. More recently it has been
regarded as suitable production route for carrier-free 64Cu [56]. The cross sections for
68Zn(p,αn) increases rapidly up to about 7 mb at 20 MeV, and thereafter slowly [56].
Below 40 MeV the formation of 64Cu is dominated by 68Zn(p,αn) due to the high
reaction threshold of the 68Zn(p,2p3n)64Cu process [56]. Formation of 67Cu becomes
significant above 25 MeV, thus the optimum energy range for production of carrier-
free 64Cu is 25→10 MeV yielding 67 MBq/µAh. Irradiating at higher energies increases
significantly the yield: 185 MBq/µAh at 37→20 MeV. Despite the 68Zn(p,2p)67Cu low
cross section (maximum of 4 mb, [69]), longer-lived 67Cu is co-produced yielding at
contamination level of 1% at 5 h after EOB [57]. Low proton energies must be avoided
to prevent production of stable copper via 68Zn(p,α)65Cu, which has a positive Q-
value and cross section of 2 mb at 5.5 MeV [70]. This last reaction has yet to be
investigated at higher energies. Proton irradiation also yields significant quantities of
gallium radioisotopes. The cross sections for 68Zn(p,2n)67Ga is much higher than for
68Zn(p,αn)64Cu: it has a peak of 700 mb at 20 MeV, then declines to 300 mb at 30
MeV. Below 20 MeV the 68Zn(p,n)68Ga channel opens and reaches a maximum of 900
mb at 12 MeV [71]. And even the reaction 68Zn(p,3n)66Ga has a moderately high cross
section: low at 19 MeV but increases to 180 mb at 35 MeV [69].
The rather low yield of 64Cu and low SA (1.2 ·1015 Bq g−1 Cu [68]) from 68Zn(p,αn)
cannot compete with 64Ni(p,n) [56]. Using the 37→20 MeV energy range for 68Zn(p,αn)64Cu
complements the optimum energy range 70→35 MeV for 66Zn(p,2pn)64Cu. This would
suggest the potential for increasing yields from a single irradiation by using tandem
targetry at a medium energy cyclotron. However, a minimum cooling period of 34 h is
required to decay out the higher-yielding contaminant 61Cu from the proton bombard-
ment of 66Zn [57].
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2.3 Neutron irradiation of zinc
Radionuclide production in a reactor most commonly utilizes the (n,γ) process, which
leads to a low SA unless the activated product decays to a daughter radionuclide that
can be radiochemically separated to a high SA [72, 73]. The cross sections for (n,p)
processes are generally low [47], and the carrier-free production of 64Cu via 64Zn(n,p)
induced by fast neutrons is no exception [53].
Comparison of the experimental cross section data (EXFOR) for 64Zn(n,p)64Cu with
the results of nuclear model calculations (STAPRE and EMPIRE) reveals considerable
discrepancies in the experimental data [73]. Spectrum average cross sections have been
measured typically using neutron field generated via break-up of 14 MeV deuterons
(9Be(d,n)10B) on a thick beryllium target [72]. As far as the (n,p) reaction is concerned,
the 14 MeV d(Be) neutrons may give to a first approximation a cross section comparable
with other fast spectral neutrons, e.g. a lead target irradiated with relativistic 1 GeV
protons yields spallation neutrons with an average energy of 3.98 MeV [74]. A 14 MeV
d(Be) breakup neutron source has a maximum flux density at 2.5–3.5 MeV neutron
energy (Figure 2.3) [73].
The cross-section average over a 235U fission neutron spectrum has been exam-
ined by the reaction induced on zinc by the epi-cadmium spectrum (epithermal and
fast neutrons) of a reactor. Irradiating the zinc under a cadmium cover permits only
the fast component of the neutron flux transmit to the irradiation position with an
energy distribution similar to that of an undisturbed 235U fission spectrum. The fis-
sion spectrum-averaged cross section is 37.4 mb [75]. The spectrum averaged cross
section from 14 MeV d(Be) breakup neutrons is 132 mb, i.e. 3.5 times higher [72].
The IAEA Activation file is recommended as the best fit to the data over all neutron
energies [58,73].
The averaged cross section for the competing reaction 64Zn(n,2n)63Zn is very low
at 0.0234 mb [50]. The low yield combined with the relatively short half-life (38 min)
make 63Zn a trivial contaminant. A boron shielded facility that will minimize thermal
neutron reactions during irradiation, and thus substantially reducing undesirable co-
production of zinc radionuclides [76].
During neutron irradiation also stable 65Cu is formed via the route 64Zn(n,γ)65Zn→65Cu,
i.e. the theoretical SA cannot be reached because of 65Cu from decay of 65Zn formed
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Figure 2.3: Energy spectrum of 14 MeV d(Be) neutrons. Figure from [73].
via neutron activation of zinc [77]. A typical SA of 3 ·1015 Bq g−1 Cu, which is 50 times
lower than theoretical maximum, can be increased by reducing copper contamination,
increasing the amount of zinc target material, using boron shielding [77], irradiating in
a more intense fast neutron flux and thus also in a more intense thermal neutron flux.
At a flux of 4 · 1017 m−2s−1 it would be feasible to attain 4 · 1016 Bq g−1 Cu 8 h after
EOB, i.e. only 3.5 times lower than theoretical maximum [77].
Irradiation of 2 g natZn for 24 h in a medium flux thermal reactor yields 17 GBq 64Cu
and a minor radioisotopic impurity of 0.018 GBq 67Cu (t1/2 = 62 h). The yield of
64Cu
could be increased up to 35 GBq if a 100% pure 64Zn target material were used (and also
the 67Cu impurity would be eliminated). A reactor target must be substantially larger
than an accelerator due to lower particle flux, thus the cost of enriched reactor target
material would be too high. An epi-cadmium experiment under similar conditions (2.5
g natZn, fast neutron flux of 7.5·1013 cm−2s−1 for 24 h) yielded 15 GBq of 64Cu and 0.016
GBq of 67Cu at EOB [78]. Thus yields from irradiation by thermal and epi-cadmium
(epithermal and fast) neutrons are very similar.
If a harder neutron spectrum is used then yields could be improved considerably [72].
Any of the four major quasi-monoenergetic neutron sources (p(Li), dd, dt, d(Be))
would be useful [72]. However, to date none of these sources has been constructed with
the neutron intensity comparable to that in a nuclear reactor. The optimum neutron
sources for 64Cu production would be a fusion reactor and a spallation neutron source.
The fusion reactor has not yet been realised [72]. And only three of the new generation
of high-flux spallation neutron sources will be online in the world within the next few
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years: the American SNS [79], European ESS [80] and Japanese JSNS [81]. However,
their locations and investments costs will put them out of reach of routine biomedical
64Cu production.
2.4 Nickel targets and radiochemical separation
2.4.1 Nickel targetry
One of the main concerns in accelerator targets is the deposition of power in the material
during irradiation. If the power deposited exceeds the ability of the target to remove
the heat, the target will eventually be melted, volatilized or reduced in density to the
point where the yield will be drastically reduced. Therefore it is necessary to remove
effectively the heat generated by the passage of the beam. There a three modes of heat
transfer which are active in targets: conduction, convection and radiation. Radiation is
only a significant mode of heat loss at high temperatures, and convection transfers heat
in only gas and liquid targets. For solid targets heat usually flows through the target
matrix mainly by conduction. Thus the interface between the solid target material and
backing material is important for efficient heat transfer to the cooled surface where the
heat is usually removed by high-pressure water flowing against the back of the backing
material [49]. It is for this reason that groups producing 64Cu from nickel targets
have used exclusively electrodeposition of enriched 64Ni onto the target disc despite
the technical challenge in obtaining a sufficiently thick nickel layer. In addition, some
groups employ supplementary cooling of the target by high-pressure He gas flow over
the target surface.
It is important to choose a target disc material with low activation material, high
thermal conductivity, high tensile strength and that is insoluble in the solvent used
to remove the electroplated 64Ni and its products. Attempts to deposit nickel on
aluminium from low electrolytic nickel concentrations (due to high cost of material)
have been unsuccessful [82]. Typically 64Ni is electrodeposited on gold of high purity.
One group, however, reports using a rhodium target disc [83]. The noble metal rhodium
is inert to all mineral acids and aqua regia and has a high tensile strength. It shows little
activation when irradiated with low energy protons; the only radionuclide produced in
the disc is 103Pd (t1/2 = 17.0 d) which emits only low energy radiation. Target discs
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are usually of two types: simple circular disc, or rectangular plates polished with a
relief cut on one side for efficient water cooling to the rear of the target [11].
It is important to keep all reagents metal-free, and to pretreat all glassware and tools
with HNO3 or HCl in order to minimize contamination with metals and a reduction
in the radiochemical purity and SA of 64Cu [60]. Isotopically enriched 64Ni is available
in powder form. To produce a high SA of 64Cu it is first necessary to remove the non-
radioactive copper from commercially supplied 64Ni by ion exchange chromatography
[11]. The electrolytic solution is then prepared by dissolving 64Ni in hot 6 M HNO3,
evaporation to dryness, treating the residue with a few drops of conc. H2SO4, dilution
with water and finally neutralisation with NH4OH. The electrolyte then consists of
(NH4)2Ni(SO4)2 at a concentration of 1.5 mg mL
−1 [82]. The electrolytic cell is made
of glass and is held between two insulating plates (Teflon rings) held together by long
screws (Figure 2.4). The target disc is placed on top of the cathode support plate in
a Teflon mask that delimits the surface area to be irradiated. The anode is made of
graphite and is rotated during electrolysis to agitate the solution and maintain a flow of
fresh electrolyte to the substrate surface [12,84]. The electrolytic solution is transferred
to the cell, and dilute NH4OH is added until pH 9 to prevent hydrogen evolution at the
cathode competing with metal deposition [85]. A 2.0–2.5 V potential across the cell is
adjusted such that a current value of 2 mA can be maintained. The electrolysis time is
5–8 hours, deposition yields vary considerably (30–100%), and thicknesses are 0.6–1.3
mg cm−2 [82]. Alternatively the nickel is pulse-layered onto the gold surface using a
platinum wire electrode at 4 mA (50 ms forward, 250 ms off) for 8 h, depositing 17 mg
cm−2 of nickel on the exposed surface [11].
The target disc is held inside a target assembly during irradiation either normal or
inclined to the beam. Figure 2.5 illustrates different types of such assemblies. Alter-
natively a target plate is mounted onto the internal inclined probe of a cyclotron [11].
Efficient water and helium cooling permits target currents of 40–60 µA. Automated
removal of the irradiated disc to a shielded container or hot cell significantly reduces
radiation exposure to the production radiochemist and permits safer, more rapid access
to the accelerator for other work.
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Figure 2.4: Electrodeposition cell used for plating low concentrations of nickel onto a
gold disc. Figure from [12].
2.4.2 Radiochemical separation from nickel targets
In addition to 61Co and 64Cu produced from 64Ni, one can also get radionuclides 57Ni,
55−58Co and 60,61Cu produced from isotopic impurities in the nickel target. Some have
long half-lives and so need to be separated from 64Cu to avoid unnecessary radiation
exposure to the patient. Many methods can be used for the separation of copper
from nickel and cobalt, such as precipitation, extraction, electroplating, but only ion-
exchange is suitable for separation of chemically-acceptable, carrier-free 64Cu [59].
Target material is processed at ≥ 12 h after EOB (to permit decay of short-lived
radioactive impurities) using a remote or semi-remote apparatus in a hot cell (Figure
2.6). The target plate or disc is mounted in Teflon holder exposing only the irradiated
surface. If dissolving irradiated nickel by exposing whole gold disc to acid, then it is
first necessary to clean disc well because contaminant copper from cooling water can
reduce SA significantly. The irradiated nickel containing copper and cobalt is dissolved
in 6 M or conc. HCl at 90 ◦C (adding a few drops of 20% H2O2 speeds up dissolution
of the target and ensures copper in the Cu(II) state). The solution is transferred onto
an anion exchange column (Cl− form), where radiation detectors monitor the elution
of activity from the column. Elution of the column with 6–10 M HCl recovers all of the
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Figure 2.5: Various designs of solid target assemblies; water-cooled targets on the left,
water- and helium-cooled targets on the right. Upper left: Classic target used in the
pioneering 64Cu production work by [12]. (a) The target disc is held in place by chamber
vacuum and a pneumatically controlled air cylinder provides the water seal. Cooling
during irradiation is by water flow through the air cylinder head to back of the disc. (b)
After irradiation, water is purged from the air cylinder head and the head is retracted.
The disc is ejected by a small overpressure of dry nitrogen in target chamber. Upper
right: Amore modern design that incorporates gas cooling to the front of the target disc
by helium gas flow (3) which is isolated from the accelerator vacuum by an aluminium
window (2). The target disc is held in place by tightening the threaded water-cooling
assembly (5) [83]. Lower left: Example of a high-power, low-angle solid target system
yet to be used in 64Cu production. The ion beam grazes the target surface at 7◦,
thus distributing power over a larger surface area, permitting more efficient water-
cooling and increasing the effective target depth. The target assembly can be removed
remotely and fitted to an etching vessel for chemical removal of irradiated material [86].
Lower right: The compact solid target irradiation system (COSTIS) developed for easy
connection to any standard internal or external beam port through by using a quick-
connection flange (1). A titanium window (11) separates the helium cooling loop (5,10)
from the vacuum, and a water jet (8) cools the back of the target. The target disc
is loaded manually before irradiation and locked in position by pneumatic actuators.
By reversing the action of the actuators the irradiated target disc is released into a
shielded transfer container conveniently placed below COSTIS before irradiation [87].
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64Ni target material while 64Cu is retained. [64Cu]CuCl2 is subsequently eluted with
water or 2 M HCl in first fraction within 30 min. and reduced to dryness under argon
gas, then taken up in water and used as a stock solution. Radiochemical purity can
be evaluated by γ-spectroscopy. The yield of 64Cu is typically 80%. The yield could
be increased to 95% by collecting later fractions, but this would introduce some 61Co
impurity (< 3%). [11,12,53,54]
There are several methods to recover the 64Ni for reuse. In one of the more so-
phisticated methods (2.7) the 6 M HCl fraction containing nickel is heated to 150 ◦C
and evaporated to dryness in a silica glass flask [60]. High purity water is added and
complete evaporation performed again. The residue is heated to 900 ◦C in an oven
for over 24 h converting the nickel to NiO, which is then ready for target preparation.
This method is reliable for recycling using electrodeposition because the nickel target
was returned to the initial form of NiO. Moreover, recycled NiO could be used directly
for the subsequent production run. Electroplating with recycled nickel is accomplished
as well as with nickel used directly from the supplier, suggesting that heating at 900
◦C for 24 h disintigrates effectively some inorganic nickel compounds. The recycling
efficiency is 94%, so the cost of one production run is quite inexpensive.
The ion exchange methods described above do not effectively separate copper from
cobalt. A better separation method developed recently involves two anion exchange
steps [59]. An ethanol-HCl eluting system is used first to separate copper from nickel
and cobalt, and then the expensive nickel is separated from cobalt by using a 9 M
HCl eluting system. The procedure yields carrier-free 64Cu from irradiated 64Ni, with
decontamination of cobalt from copper > 99% and the recoveries of 64Cu and 64Ni are
> 95 %.
Another technique reported recently uses spontaneous electrochemical deposition to
separate copper from nickel [83]. Nickel chloride solution containing 64Cu is converted
into sulphate in 1 N H2SO4 and transferred into an electrochemical cell (U-tube with a
double diaphragm). A platinum net is inserted into the side of the cell containing the
irradiated material, and the other side filled with saturated NiSO4 solution and a nickel
plate inserted. Both electrodes are connected and the 64Cu deposits quantitatively on
the platinum net within 15–30 min. Removal of 64Cu from the platinum net proceeds
by dissolution in nitric acid. This method yields 98% of the 64Cu, and 95–98% recovery
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Figure 2.6: Example apparatuses for the remote-controlled separation of 64Cu from
irradiated nickel targets by anion exchange chromatography. Both apparatuses consist
of six main components: a heating vessel for the dissolution of irradiated nickel, an
anion exchange column, solvent reservoirs for elutions, collection vials, electric valves
that can be operated remotely, and either vacuum or argon gas to drive the solvents.
Figures taken from [11,60].
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Figure 2.7: Schematic representation of the 64Ni recycling process following radiochem-
ical separation of 64Cu. Figure taken from [60].
Figure 2.8: Two stage ion-exchange procedure advocated by [59]. (a) Separation of Cu
from irradiated Ni target by eluting Ni and Co with ethanol-HCl and then eluting Cu
with water. (b) Recovery of Ni from Ni-Co fraction by first eluting Ni with 9 M HCl
and then Co with 2 M HCl. Figure taken from [59].
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of the 64Ni.
2.5 Zinc targets and radiochemical separation
2.5.1 Zinc targetry
Nearly all 64Cu production by ion irradiation of zinc has been for cross section de-
terminations. There has been relatively little development of high-performance zinc
accelerator targets. Thin targets are prepared by electrolytic deposition on gold. The
zinc is dissolved in 1 M HCl and transferred to electrolytic cell. Electrolytic deposition
is carrier out on gold foil at 5 V, 0.3 A. The platinum foil anode is rotated to avoid
contacting of the originating gas bubbles with the gold cathode foil [56].
The charge neutrality of neutrons results in only minor heat transfer to material
they pass through due. Thus neutron irradiation targets do not require the same degree
of cooling as accelerator targets, and the target material can conveniently be in powder
form. High-purity zinc oxide powder is weighed in a quartz ampule, which is flame-
sealed at the open end and placed in an aluminium irradiation capsule. The quartz
ampule can be wrapped in cadmium foil to curtail the thermal neutron flux density
and thus suppress the production of (n,γ) products. To prevent non-radioactive copper
contamination strict acid-wash procedures are applied to all quartz and plasticware.
[77,78]
2.5.2 Radiochemical separation from zinc targets
The techniques for separation of 64Cu from irradiated zinc targets is more heteroge-
neous than for separation from nickel targets. A decade ago comparison of techniques
suggested that ion exchange chromatography performed best [88]. Precipitation was
ruled out because it requires addition of a carrier. A single electrolytic cycle gives a
high-purity product at low yield; repeated cycles improve the yield at the expense of
purity. However, the recent development of other techniques means that there does
not currently appear to be consensus on the optimal technique.
30
Cation exchange chromatography
Cation exchange chromatography of neutron-irradiated zinc powder starts after a suit-
able cooling period [77]. The aluminium foil is removed, the quartz ampule scratched
with a knife around its circumference at the middle of the ampule and broken into two
halves. The target material is poured into a tube and dissolved with HNO3 and HCl,
then transferred to a cation exchange column (Cl− form) and washed with 8 M HCl.
Copper is eluted with 1 M HCl noting visually the lighter colour of the acid elution
front. Zinc is retained on the resin. The yield of 64Cu in the eluate is > 90%. Decon-
tamination factors of the resin are > 108. Analysis by cathodic stripping voltammetry
revealed that carrier copper in the 64Cu eluate could be reduced effectively by using
high-quality reagents in a clean working cabinet, and that the zinc oxide is not the
major source of copper.
The analogous procedure for accelerator targets has been developed into an efficient,
simple, reproducible and hot cell-compatible technique that gives high purity, 90%
yields after 4.5 h [88]. The procedure is descibed in Figure 2.9.
Liquid-liquid extraction
Early extraction methods proceeded by dissolving the zinc at 400 K in 30% HCl,
repeated drying and dissolved in 0.5 M HCl, addition to organic phase 0.01% dithizone
(diphenylthiocarbazone, highly selective for copper) in carbon tetrachloride (CCl4),
re-extracted of the copper with 7 M HCl and H2O2, transfer to a cation exchanger,
and finally elution of the copper with 2 M HCl [88]. However, to attain sufficient
copper purity, the extraction had to be repeated several times which lowered yield
excessively. Handling halogenated organic solvents containing radioactive waste was
also problematic.
Although CCl4 permits an almost quantitative re-extraction, it is an unsuitable
solvent for pharmacology. Thus other organic solvents (chlorinated hydrocarbons) were
evaluated and the method developed further [89]. It was found that 0.01% dithizone in
chloroform (CHCl3) worked well as the organic phase when washed with 0.1 M HCl and
the copper re-extracted with 6 M HCl. A > 90% recovery could be attained after three
re-extractions. Instead of ion exchange purification, the extractant was evaporated and
baked at 300 ◦C for 15 min to decompose possible pyrogens, then dissolved in 0.05 M
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Figure 2.9: A simple, hot cell-compatible and rapid cation ex-
change apparatus for the separation of radiocopper from irradi-
ated zinc and co-produced contaminants [88]. Irradiated zinc disc
(3) is dissolved without heating in vessel (2) by addition of conc.
HCl (1). The volume of conc. HCl is defined so that following
complete dissolution the solution is 6 M HCl, and so it can be ap-
plied directly to the cation exchange column (4) pretreated with
6 M HCl. After washings with 6 M HCl, gallium stays quantita-
tively on the column, whereas copper, cobalt, nickel and zinc pass
through to the mixing vessel (7). The copper-containing solution
pH is adjusted carefully to 3.5 by slow addition of 10 M NaOH (5)
and monitored with an electrode (6) (a lower pH would reduce
binding of copper on the next column resulting in progressive loss
during washing; a higher pH would result in partial precipitation
of Zn(OH)2 which would impair the next step due to obstruc-
tion). The mixed solution is filtered (12) to remove any Zn(OH)2
precipitate, and run onto the second cation exchange column (13)
pretreated with 1 M HCl. Washing the column with 0.001 M HCl
(9) removes cobalt, nickel and zinc to the waste (15). However,
a small residue of zinc remains on the column. The copper is
eluted with 2 M HCl (10) onto an anion exchange column (14)
pretreated with 2 M HCl. The front of the eluate is less than 2
M HCl because it contains a small amount of the 0.001 M HCl
washing solution. This concentration is not high enough to re-
tain the last traces of zinc reliably during elution of copper. The
2 M HCl left on the anion exchange resin after preparation thus
prevents the breakthrough of zinc. Figure taken from [88].
HCl and sterile filtered.
Carrier-free 64Cu can also be recovered quickly from a deuteron-irradiated zinc
target by extraction of the ionic associate of copper with diantipyrylpropylmethane (R)
from iodide-containing sulfuric acid solutions in chloroform. In acidic iodide solutions
copper exists as Cu(I) forming CuI –2 anionic complexes, which are many orders of
magnitude more stable than the analogous complexes of Zn(II) and Ga(III). Thus in
this system there is a great contrast in the distribution factors for copper and for zinc
and gallium (Figure 2.10) [90].
Maximum distribution factors are attained at 0.05 M KI and 0.1 M R (Figure
2.11). However at these concentrations the extraction is deficient. When [R] > [I−] the
copper iodide complex decomposes: CuI –2 +2RH
+ −→ Cu++2RHI. Yet at [R] [I−]
the iodide ion competes with the metal anionic complex for the reagent: RHCuI2 +
I – −→ RHI + CuI –2 . The optimum composition of the aqueous phase is 1 M H2SO4 +
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Figure 2.10: Distribution factors (Kd) for extraction of copper (1) from zinc (2) and
gallium (3) in iodide solutions as a function of acidity. Aqueous phase H2SO4–0.1 M
KI, organic phase 10−2 M R in CHCl3. Figure taken from [90].
Figure 2.11: Distribution factors (Kd) for copper in CHCl3 as a function of [I
−] (left)
and [R] (right). Figure taken from [90].
0.1 M KI, where copper is extracted in the form of an ionic associate of CuI –2 with the
protonated form of the reagent RH+. In practice, irradiated zinc is dissolved in HCl,
and H2SO4 is added in the amount required to attain 1 M H2SO4 and 2 M zinc in the
final aqueous phase. The solution is evaporated until H2SO4 vapour appears and is
then cooled. The residue is dissolved in aqueous KI to attain 0.1 M KI. The copper is
extracted with an equal volume of 0.02 M R in CHCl3, and the organic phase washed
with the equilibrium aqueous phase. Antipyrine derivatives in acidic halide solutions
form readily extractable ionic associates (in the protonated form) with anionic metal
halide complexes. So, the simplest way to backwash copper is by stirring the organic
phase with water or an alkaline solution [90].
The most recently developed method is extraction into iso-propylether from inor-
ganic HCl as complexant, followed by anion exchange chromatography, without using
any organic chelating agent. The zinc target is dissolved in 7 M HCl, dried and re-
dissolved in 7 M HCl. Gallium is extracted as chlorocomplexes from HCl in isopropyl
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Figure 2.12: Temperature dependence of the vapour pressures of copper, zinc and
gallium. Figure taken from [91].
ether; less than 0.05% copper is co-extracted with gallium. The Zn-Cu aqueous solution
is diluted to 2–3 M HCl and transferred to an anion exchange resin. Zn(II) is strongly
absorbed onto the resin as anionic chlorocomplexes, while Cu(II) is not retained by
the resin being present as Cu(II) and CuCl+ aquacations. The radiochemical yield for
copper is > 80% [7].
Vacuum distillation
A recent technique developed for isolation of 67Cu from zinc uses vacuum distillation
[91]. The procedure is based on the difference of evaporation rates and partial vapour
pressures of the elements being separated (Figure 2.12). It requires the use of an inert,
high-melting target substrate; tantalum is reportedly the most suitable: it has a lower
thermal conductivity than silver or zinc but an optimal combination of strength and
mechanical properties. The isolation is performed at 10−6 mbar in a vacuum chamber
fitted with a water-cooled condenser and a furnace. The yield of copper is 98%. The
report of this method does not mention though how copper is removed from target
plate.
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Chapter 3
Ligands for 64Cu
The importance of ligands in modifying the biological effects of metal-based pharma-
ceuticals cannot be overestimated. Ligands modify the systemic availability of a metal
ion and can assist in targeting specific tissues or enzymes [92]. Either 64Cu is taken
up in complexes that are target molecules in their own right, or it is coordinated to
a bifunctional ligand that bonds covalently to a targeting macromolecule. The latter
group comprises mostly ligands that are not specifically designed for copper, having
largely been designed for use with lanthanide ions, and do not have desirable overall
neutral charge characteristics, do not label easily, and are not necessarily stable with
respect to reduction to Cu(I) [93]. Due to their great potential, the development of
bifunctional copper chelators is an active field of research.
Production of 64Cu almost invariably leads to the final extraction of aqueous 64CuCl2,
which forms the starting point for the synthesis of 64Cu radiopharmaceuticals. This
material is sufficiently labile to permit rapid synthesis of Cu(II) compounds simply by
addition of the ligand at an appropriate pH at room temperature [10]. Synthesis of
Cu(I) complexes requires a reducing agent. Fortunately, many of the ligands that sta-
bilise Cu(I) act as sufficiently strong reducing agents without the need for exogenous
reductants.
3.1 Copper coordination chemistry
The development of copper ligands forms an important part in inorganic coordination
chemistry. Vast numbers of copper complexes are known, and their research yields
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hundreds of articles every year. This section reviews pertinent, basic aspects of copper
coordination chemistry before embarking on a discussion of ligands specific to 64Cu.
Due to the very low molar concentrations of 64Cu in the synthetic preparation of ra-
diopharmaceuticals, only mononuclear complexes are of interest. More comprehensive
reviews of copper coordination chemistry that also include bi- and polynuclear com-
plexes are in the literature, e.g. [94–98].
The oxidation state of copper is controlled by its chemical environment. In the
presence of highly covalent, polarisable ligands such as thioethers, phosphines, nitriles
and iodide ion, Cu(I) is stable and forms stable complexes with these ligands. Where
the available interacting species are less polarisable and show less covalency (e.g. H2O,
ClO –4 and SO
2 –
4 ) disproportionation of Cu(I) to give Cu metal and Cu(II) complexes
is favoured [10]. The relative stability of oxidation states I and II (as manifested by
the redox potential of their interconversion) can be controlled by choice of donor type.
The Cu3+ ion may be formed under certain conditions, but it is a powerful oxidant
and is not a stable species in biochemical systems [99].
3.1.1 Copper(I)
Because the third electron shell is filled, Cu(I) complexes are diamagnetic [10]. There
are no ligand field splittings, so coordination numbers and geometries are dictated
principally by the steric and conformational demands of the ligands. Coordination
numbers 2 (linear), 3 (trigonal planar) and 4 (tetrahedral) are well established. Cu(I)
prefers soft polarisable ligand donor groups such as thioether, phosphine, alkene, nitrile,
isonitrile, iodide, cyanide and thiolate.
The stereochemical flexibility of Cu(I) means that the coordinate bonds are labile,
and ligand exchange processes are often rapid unless some ligand steric factor impedes
reactivity (e.g. blocking of associative mechanisms by steric hindrance, or blocking of
dissociative mechanisms by strong chelate effects) [10].
3.1.2 Copper(II)
Cu(II) has d9 configuration, and therefore its mononuclear complexes are paramag-
netic [99]. The unsaturated d shell gives rise to a ligand field stabilisation energy,
inducing the metal to exhibit stereochemical preferences that may compete with those
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of the ligands [10]. Cu(II) complexes with coordination number 4 exhibit square planar,
tetrahedral and all intermediate geometries. The d9 configuration causes the octahe-
dral 6-coordinate and tetrahedral 4-coordinate complexes to be Jahn-Teller distorted to
remove degeneracy, although the degree of distortion varies considerably [100]. This is
usually manifested in an axial elongation in octahedral complexes or a tetragonal com-
pression in tetrahedral complexes. In both cases, the limiting extreme of the distortion
is square planar. Some octahedral Cu(II) complexes even execute a dynamic (pulsating)
Jahn-Teller behaviour, where the direction of elongation varies rapidly [97]. Cu(II) is
distinct from Cu(I) in its donor group preferences: nitrogen ligands (e.g. amines, Schiff
base, pyridines and bipyridyls) and anionic ligands (e.g. halides and β-diketones) [10].
Cu(II) is less labile towards ligand exchange than Cu(I), partly because the ac-
tivation energy for ligand exchange reactions will include a ligand field stabilisation
enthalpy term [10].
3.1.3 Copper(III)
Cu(III) requires stabilisation by particularly strong pi-donating anionic ligands [10].
Its complexes require high pH to minimise competition with protons, since the ligands
have a high pKa values. The d
8 configuration leads usually to square planar geometry.
Most Cu(III) ligands contain deprotonated amide nitrogens, but Cu(III) is also found in
some macrocyclic tetraamine, tetradentate Schiff-base and dithiocarbamate complexes.
3.2 Metal-essential ligands
Metal-essential ligands incorporate radiocopper where the principle design aim is not
kinetic stability, and where the biodistribution depends primarily on other molecu-
lar properties of the complex itself [10]. There is not necessarily a biological carrier
molecule involved. The most extensively studied metal-essential ligands forming com-
plexes with 64Cu are the bis(thiosemicarbazones) (BTS) (Figure 3.1). Their role in
biomedicine is discussed in section 4.2.
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Figure 3.1: Structures and abbreviations of Cu-BTS complexes. Figure taken from
[101].
3.2.1 Bis(thiosemicarbazones)
The reduction potential and lipophilicity of Cu(II)-BTS complexes can be controlled
independently by alkylation in the carbon backbone and the N-termini of the ligand,
allowing optimisation of radiopharmaceuticals strongly selective for hypoxic tissues
[101, 102]. The synthesis of 64Cu-BTS radiopharmaceuticals is simple and rapid. For
instance, in the preparation of 64Cu-ATSM, 64CuCl2 stock is added to 0.2 M glycine,
to which is then added H2ATSM in dimethylsulfoxide (required due to its lipophilicity)
[10, 11]. The reaction mixture is vortexed for 30 s and the degree of complexation
monitored by TLC. The labelling reaction is complete almost instantaneously, and
the product generally has acceptable radiochemical purity (95–99%) without further
purification.
All Cu(II)-BTS complexes have close to a planar structure with three five-membered
chelate rings [103]. Distortions from planarity are slight and only present when there is
significant intermolecular interactions (mainly pairs of N−H−N and N−H−S hydrogen
bonds). These give rise to cross-linked flat or helical ribbons of complexes. Alkylation of
the N-termini interrupts hydrogen bonding, allowing the complexes to become planar,
but does not otherwise affect the coordination sphere. Alkylation of the backbone
carbon atoms increases the backbone C−C bond length, allowing the metal to fit
better into the ligand cavity with shorter Cu−S bonds.
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Figure 3.2: Schematic molecular orbital diagram for Cu(II/I)-BTS complexes showing
the orbital degeneracy of the reduced state. Orbitals with similar spatial distributions
are connected by dashed lines. Figure taken from [107].
The exact reduction mechanism and stabilities of Cu-BTS complexes is still being
investigated [104–107]. The most recent study [107] found reduction to be a prereque-
site for protonation of the complexes, suggesting their transport in the blood stream
as neutral species, and the mechanistic sequence to be a sequential electrochemical-
chemical process. Figure 3.2 shows representative molecular orbital diagrams for
Cu(II)- and Cu(I)-BTS complexes. For the Cu(II) oxidation state both the highest
occupied molecualr orbital (HOMO) and lowest unoccupied molecular orbital (LUMO)
are beta spin-orbitals β1 and β2, respectively. This situation occurs in the due to the
energy splitting between the differentially occupied α and β orbitals. Reduction is
metal centred, and electron donating groups at the R1 and R2 positions (Figure 3.1)
positions destabilise the Cu(I) α2/β2 HOMO by reducing the extent of delocalisation if
electron density from the copper ion to the ligand. This raises the energy of the HOMO
and destabilises the complex as a whole, thereby lowering the one-electron reduction
potential of the Cu(II) partner.
Although non-radioactive Cu-BTS complexes were developed already in the 1960s
due to their anti-tumour activity [108–110], the synthesis of BTS proligands is still
being optimised, for instance, to prevent oxidative degradation [111]. The potential
of novel BTS appendages as specific hypoxia markers also continues to be a current
topic in structural inorganic chemistry [112,113]. Bis(selenosemicarbazones), where the
oxidation potentials are shifted due to the replacement of S by Se, are being assessed
as possible radiopharmaceuticals labelled with 64Cu [114,115]. Very recently there has
been a marriage between BTS and bifunctional ligands [116]: BTS-pyridylhydrazine
hybrid ligands have been synthesised, which retain the favourable characteristics of
39
BTS ligands but also have a pendate carboxylate arm that can conjugate to amino
acids.
3.2.2 Other metal-essential ligands
Biomedical applications have exploited the specific tissue affinities of other metal-
essential ligands labelled with radiocopper. Such ligands include the versatile diphos-
phines, and for oncology porphyrins and bleomycin, for neurology polyaminocarboxy-
lates, Schiff (tetradentate [N2O2]
– ) bases and dithiocarbamates, for hepatology super-
oxide dismutase and penicillamine, and for inhalation studies β-diketonates [10, 117].
Their development has diminished recently, and they are now eclipsed by the BTSs
and bifunctional ligands.
3.3 Bifunctional ligands
Attachment of radioactive metal ions to molecular targets requires the use of a bi-
functional ligand, which complexes the radioactive metal at one site and covalently
bonds to the targeting agent at another site [118]. A range of bifunctional ligands have
been investigated for labelling with 64Cu. Figure 3.3 illustrates the most common pro-
ligands and ligands, but others include diiminedioxime [119], bis(diphosphine) [120],
quinoxaline dioxide [121] and triaminocyclohexane [122].
The choice of bifunctional chelate moiety is highly dependent on the stability it
confers to the metal centre [123]. Originally, thermodynamic stability of the complex
was thought to be the decisive factor. However, in radiopharmaceutical development
kinetic stability is more important, since the radioisotope is continuously decaying and
its dissociation from the complex needs to be very slow or negligible so that it is not
lost during the lifetime of the target agent in vivo. Multidentate macrocyclic complexes
are good choices in this respect because individual metal donor bond ruptures can be
fast but their recoordination can also be very fast as the metal ion is never very far
away from the donor atom. It is desirable that a bifunction ligand
• coordinates the 64Cu ion rapidly (within minutes) and quantitatively at micro-
molar to nanomolar concentrations,
• preferentially binds 64Cu in the presence of contaminating metal ions,
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Table 3.1: Conditions for complexation of 64/67Cu with selected bifunction ligands.
Table taken from [118].
• forms discrete 64Cu complexes to prevent lengthy purification procedures and the
need for excess ligand,
• coordinates the 64Cu ion in pH range 4–9, and at mild temperatures (e.g. 20–37
◦C) so as not to damage the sensitive targeting agents,
• does not release 64Cu to adventitious natural ligands in the biological fluid (metal
binding proteins), and
• does not readily exchange with Cu2+ and Zn2+ in vivo [118].
The conditions for complexing 64Cu differ between ligand classes (Table 3.1). Tetraaza-
macricycles, SarAr and TETA complex in ≤ 30 min, whereas the polyaminophospho-
nates require extended incubation times, and bridge-cyclams require agressive heating
over long periods of time.
3.3.1 Aza macrocycles
Tetraazamacrocyclic ligands are the most widely used bifunctional chelators for at-
taching radiocopper to antibodies and peptides due to their relatively high kinetic
stability [124–127]. Employing a structurally reinforcing cross-bridge enhances in vivo
stability by reducing metal loss to proteins [128]. The cyclam ligands, especially, have
been the focus of recent research examining the biological stability and in vivo be-
haviour with different functionalized, pendant-armed derivatives [129–131]. The pres-
ence, for example, of a methylphosphonate pendant arm aids complexation selectivity
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Figure 3.3: Parent derivatives of selected bifunctional ligands. Figure taken from [118].
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Figure 3.4: Structure of [Cu(II)-diamsar-2H]4+. Cu: large black, N: medium grey, C:
small grey. Figure taken from [118].
of Cu(II) over other metal ions [132]. Cross-bridged cyclam derivates form highly stable
complexes with Cu2+ that are resistant to dissociation in strong acid and serum, but
show variable retention in major clearance organs (e.g. blood, liver and kidney). The
hexaazamacrobicyclic cage ligand SarAr has been demonstrated to confer exceptional
stability to its complex with 64Cu [133].
An example structure of a Cu(II)-aza macrocyclic complex is [Cu(II)-diamsar-2H]4+
(Figure 3.4). It is hexadentate with all six nitrogen atoms complexing Cu2+ [118]. The
Jahn-Teller effect causes the complex to loose its D3 symmetry and form a somewhat
distorted trigonal complex. The apical nitrogens are protonated giving the complex an
overall tetrapositive charge.
3.3.2 Polyaminocarboxylic macrocycles
The preference for 64Cu complexes stabilized by polyaminocarboxylic macrocycles is
motivated by some favourable features [134, 135]: ease of synthesis, kinetic and ther-
modynamic stability, solubility in water, and resistance to metal ion exchange in vivo.
Furthermore, they are easily tailored so as to address specific issues regarding the di-
mensions of the chelating cavity, positions of the donor atoms, and the electronic and
steric nature of the peripheral ligands. Again, cross-bridging of the ligand confers extra
in vivo stability to the Cu(II) complex [136,137].
Dota is the most popular polyaminocarboxylic macrocycle for complexing 64Cu.
The complex takes the form of a cis-octahedron (Figure 3.5), where Cu2+ coordinates
with two of the macrocyclic nitrogen atoms in the equatorial plane and two carboxylate
oxygen atoms in the cis position [118]. The remaining nitrogen atoms take up almost
43
Figure 3.5: Structure of [Cu(II)-dota]2−. Cu: large black, N: medium grey, O: medium
dark grey, C: small grey. Figure taken from [118].
axial positions above and below the plane of the octahedron. The position of Cu2+
above the equatorial plane indicates that the metal ion is too large for the planar N4-
macrocyclic configuration. Importantly the Cu2+ shows preference for the carboxylic
oxygen atoms over the remaining tertiary nitrogen atoms.
3.3.3 Polyaminophosphonate macrocycles
A particular class of polyazamacrocyles bear pendant phosphonic acid groups that ex-
hibit coordination selectivity and high thermodynamic stability [138]. Protonation of
the phosphonate oxygen atom is difficult to accomplish in both the free ligand and
metal complexes. As a result, the metal complexes are stable to proton-catalysed
dissociation pathways, thus fulfilling a requirement for therapeutic and imaging appli-
cations. Structural variations of the phosphorus substituents controls effectively the
hydro-lipophilic properties of the ligand and complex, which may provide fine tuning
of conjugation with biomolecules.
Illustrative of Cu(II) polyaminophosphonate macrocyclic complexes is Cu(II)-do2p
(Figure 3.6). Reaction of do2p with Cu2+ at room temperature results in a trigonal
bipyramidal complex, which upon incubation changes to a trans-octahedral coordina-
tion sphere. Here Cu2+ is positioned with the equitorial plane of the macrocyclic ring,
and the two oxygen atoms of the phosphonate groups take up axial positions above
and below the ring.
Of the polyaminophosphonate macrocyclic complexes, 64Cu-do2p has been demon-
strated to have optimal clearance through the blood and liver [139]. 64Cu-dotp and
64Cu-do3p exhibit higher uptake and longer retention in liver, possibly because of
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Figure 3.6: Structure of [Cu(II)-do2p]. Cu: large black, N: medium grey, O: medium
dark grey, P: medium light grey, C: small grey. Figure taken from [118].
the large negative charges of the complexes under physiological conditions. All three
64Cu-labelled complexes show high accumulation in bone (likely due to the binding
of the methanephosphonate groups to hydroxyapatite), thus they may be useful as
bone-imaging agents [139,140].
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Chapter 4
Biomedical applications of 64Cu
Knowledge of copper coordination chemistry and the labelling and testing of other
copper radioisotopes over the past two decades (especially for 67Cu, e.g. [141]) has ac-
celerated the introduction of 64Cu into a wide range of applications. Some applications,
however, are unique to 64Cu due to its intermediate half-life or multimode decay.
4.1 64Cu as a biological tracer
Copper is the third most abundant metal after iron and zinc in the human body. It is
an essential micronutrient that plays a pivotal role in cell physiology and is a catalytic
cofactor in the redox chemistry of enzymes, mitochondrial respiration, iron absorption,
free radical scavenging and elastin cross-linking [97,142–144]. Copper homeostasis is co-
ordinated by several proteins such as glutathione, metallothionein, Cu-transporting P-
type ATPases, Cu/Zn superoxide dismutase, ceruloplasmin, lysyl oxidase, cytochrome
c oxidase, tyrosinase and dopamine-β-hydroxylase. An excess of free copper ions can
cause damage to cellular components. So under physiological circumstances intracel-
lular copper availability is extraordinarily restricted by a delicate balance between the
uptake and eﬄux. Delivery of copper to specific pathways and target proteins is deter-
mined by cytoplasmic transporter proteins called metallochaperones that protect this
metal from intracellular scavenging.
The chemical toxicity of copper or its impaired cellular homeostasis can lead to
several human disorders, especially neurogenerative disorders [145], that can be inves-
tigated using 64Cu tracers [143, 146, 147]. Decreased biliary copper excretion due to
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the autosomal recessive disorder Wilson disease causes gradual accumulation of excess
copper in the liver with other tissues accumulating oxidative damages, leading to liver
cirrhosis and neurological impairment. Menkes disease entraps copper in the intestinal
and kindney cells or vascular endothelial cells in the blood-brain barrier, leading to
abnormally low levels of copper in the liver and brain and the progressive neurolog-
ical impairment and death in infancy. The genetic absence of production of active
ceruloplasmin (aceruplasminemia) prevents accumulation of iron in the liver and re-
lease into the blood. In infection and inflammation, copper concentrations rise because
the metal is important for the production of hormone interleukin-2 by activated lym-
phocyctic cells and it supports the activity and effectiveness of cellular and humoral
activity. In cancer, plasma ceruloplasmin antigen or oxidase activity are positively cor-
related with disease stage, and malignant tumours have copper concentrations higher
than those of their tissue of origin. Copper may also have a role in angiogenesis —
limiting the biological availablity of copper slows tumour growth probably due to the
inhibition of angiogenesis. Prion infected cells display a marked reduction in copper
binding, and that modification of copper homeostasis plays a determinant role in the
neuropathology of transmissible spongiform encephalopathologies.
Biological assays utilize 64Cu to measure cellular copper uptake and eﬄux in order
to elucidate its physiology and pathology. Cells in vitro are labelled either metabol-
ically or pulsed with 64Cu by adding 64CuCl2,
64CuSO4 or
64Cu-l-histidine in saline
at physiological copper concentrations to the cell culture and incubating them. The
cells are then rinsed with phosphate-buffered saline and sometimes residual copper is
scavenged with EDTA. Occasionally cells are incubated in a non-labelled medium for
a chase period and rinsed again. After the cells are harvested and/or lysed, the 64Cu
activity is quantified by γ-counting in a monowell counter or by liquid scintillation. In
uptake studies the incubation of cells in a 64Cu-labelled medium is performed for var-
ious time periods; for eﬄux studies the incubation in a non-labelled medium is varied.
In some cases copper deficiency is induced by exposing cells to chelator triethylenete-
traamine (TETA) and washing with saline prior to labelling with 64Cu. In vivo studies
proceed by administering intravenously 64CuCl2 or
64Cu-acetate and by assaying blood
or tissue samples.
Recent investigations include studies on
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1. copper homeostatis and adaptation to chronic copper exposure through its trans-
port at the plasma membrane, its intestinal and hepatic absorption, and its chap-
eroning by Cu/Zn superoxide dismutase [148–152],
2. the genetic encoding for transmembrane copper transport proteins, P-type AT-
Pases [153,154],
3. the properties of brain cuproenzymes Cu-Zn superoxide dimutase and cytochome
c oxidase [155],
4. the possible role of a surface prion glycoprotein, PrPC, in brain copper binding
and oxidative stress [147,155],
5. the mechanisms of copper introduction into ceruloplasmin, the role of ceruloplas-
min in copper metabolism and the molecular pathogenesis of aceruloplasmine-
mia [142,156,157],
6. the function of immunophilin (a component of the copper eﬄux machinery) in
promoting neuroprotection from copper toxicity [158],
7. the effect of copper eﬄux transporter protein expression on the pharmacody-
namics of cisplatin, carboplatin and oxaliplatin in human ovarian carcinoma cells
with aquired chemotherapy resistance [159–161],
8. a non-invasive biomarker for indicating copper-induced cytotoxicity in erythro-
cytes [162],
9. biodistribution studies of metal-enzymes [163,164], and
10. the pathogenesis of cytochrome c oxidase deficiency [165] (Figure 4.1).
Simple compounds labelled with 64Cu have also been used in preclinical oncology
studies. For example, 64CuCl2 has been demonstrated as a probe for imaging mouse
extrahepatic hepatoma expressing a mouse copper transporter [166]. However, most
preclinical and clinical studies discussed in the following sections have used utilised the
ligands described in Chapter 3.
4.2 Hypoxia imaging and therapy
The success of 64Cu-labelled antibodies or peptides as therapy agents in solid tumours
has been limited due to heterogeneous antigen expression and low overall tumour up-
take. A characteristic pathophysiologic property of solid tumours that occur across a
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Figure 4.1: 64Cu uptake and retention in fibroblasts from controls (squares), Menkes
disease patients (diamonds) and those with cyctochrome c oxidase assembly gene mu-
tation (triangles). Menkes patients show abnornally high copper uptake and retention.
Deficiency in cyctochrome c oxidase also elevates fibroblastic copper concentrations.
The enzyme cytochrome c oxidase catalyses the reduction of molecular oxygen. Its
deficiency is found in neonatal, infantile and late onset diseases with multisystemic,
neurological and muscular symptoms, and is one of the most frequent biochemical di-
agnoses of lethal neonatal and infantile respiratory chain deficiency disorders. It can,
however, be potentially treated by copper supplementation. Figure taken from [165].
wide variety of human malignancies is hypoxia [167, 168]. Oxygen tension in tumour
tissues is significantly lower than adjacent normal tissues, and is caused by uncontrolled
cell growth and insufficient vascularization. Hypoxia can lead to ionizing radiation and
chemotherapy resistance by depriving the tumour cells of the oxygen essential for the
cytotoxic activities of these agents or indirectly by proteomic and genomic changes.
These effects can lead to increased invasiveness and metastatic potential, loss of apop-
tosis, chaotic angiogenesis, making treatment increasingly difficult. In many cases
hypoxia correlates with poor prognosis.
64Cu-BTS complexes are promising imaging and therapy agents for hypoxic tu-
mours, due to their neutral lipophilicity, low molecular weight, high membrane per-
meability, low redox potential, and rapid uptake and washout in normoxic cells. In
ischaemic rat heart tissue, 64Cu-ATSM showed high accumulation whereas perfusion
marker 11C-acetate showed low accumulation [169]. Oxygen probe measurements of in-
tratumoral hypoxia in rat prostate tumours were broadly consistent at the microscopic
level with hypoxia marker 18F-FMISO and late 64Cu-ATSM images, but not with early
64Cu-ATSM images [170]. However, both early and late 64Cu-ATSM images of human
squamous cell carcinomas were consistent with oxygen probe measurements (Figure
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Figure 4.2: Comparative serial microPET images of sequentially administered 18F-
FMISO and 64Cu-ATSM in rats bearing human squamous cell carcinoma xenografts.
Coronal sections at the mid-tumour level illustrate gross similarity in intratumoral
distributions of hypoxic tracers. Figure taken from [170].
4.2). Double-tracer autoradiography in various mouse tumour models has demon-
strated that the high 64Cu-ATSM uptake regions are hypovascular, whereas the high
[18F]FDG uptake regions were hypervascular and consist of pre-necrotic, proliferating
cells [171,172] (Figure 4.3).
Demonstrative of its therapeutic capacity, 64Cu-ATSM was shown to reduce the
clonogenic survival rate in vitro of mouse lung carcinoma cells in a dose-dependent
manner [173]. Under hypoxic conditions, cells took up 64Cu-ATSM and cell prolifera-
tion and induction of apoptosis was observed (Figure 4.4). DNA damage by radiation
emitted from 64Cu was detected. The majority of the 64Cu was taken up into the cells
in the postmitochondrial supernatant (the cellular residue after removal of the nuclei
and mitochondria), which indicated that the β− emission from 64Cu may be as effec-
tive as the Auger electrons and it potentially effects the peripheral nonhypoxic regions
indirectly.
Competing in vitro models to explain the mechanism for preferential uptake of Cu-
ATSM under hypoxic conditions have been proposed in the literature [173–175]. In
the most recent mechanistic study on 64Cu-ATSM [175], it was postulated that the
initial cellular accumulation of 64Cu is driven by translocation of 64Cu-ATSM across
the membrane followed by the reduction of Cu(II) to Cu(I) and trapping of the now
charged Cu(I)-ATSM complex (Figure 4.5). The Cu(I)-ATSM complex is not stable
and will either dissociate into Cu(I) and ATSM (which slowly clears from the cell in
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Figure 4.3: Autoradiographic images of (a) 64Cu-ATSM and (b) [18F]FDG co-injected
intraveneously into a carcinoma-bearing rabbit. 64Cu-ATSM accumulated around the
hypoxic, outer rim of the tumour mass. [18F]FDG distributed more widely, with the
highest levels in the inner tumour regions composed of pre-necrotic cells. Figure taken
from [171].
Figure 4.4: Clonogenic survival assay under hypoxic conditions of mouse lung carci-
noma cells incubated with free 64Cu (64Cu glycine) and 64Cu-ATSM. The difference in
survival rates suggest that intracellular uptake is a major factor in the efficient tumour
cell killing by 64Cu-ATSM. Figure taken from [173].
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Figure 4.5: Model for the uptake and accumulation of 64Cu in cells incubated with
64Cu-ATSM. Figure taken from [175].
the form H2-PTSM), or in the presence of oxygen, be oxidized back into Cu(II)-ATSM.
Once Cu(I) is absorbed by the intracellular copper pool it becomes subject to cellular
copper metabolism.
64Cu-ATSM has exhibited selectivity for hypoxic tumour tissue both in vitro and
in vivo, and may provide a successful diagnostic modality for the detection of tumour
ischaemia [176–178]. Nevertheless, the complex relationship between oxygenation con-
ditions, intertumoral differences, cell-line dependent kinetics of 64Cu uptake and reten-
tion of copper make it still unclear how accurately and reliably 64Cu-ATSM measures
tumour hypoxia in vivo and in clinical management [175,179–181].
A new therapy based on the co-administration of two cytotoxic compounds, 2-
deoxy-glucose (2-DG) and 64Cu-ATSM, exploits both the high glucose use and hypoxia
of solid tumours [182]. 64Cu-ATSM localizes to hypoxic regions, whereas 2-DG selec-
tively accumulates in cancer cells and interferes with energy metabolism, resulting in
cancer cell death. 2-DG was shown to potentiate the effect of 64Cu-ATSM on tumori-
cidal activity and animal survival.
64Cu-BTS complexes other than 64Cu-ATSM are less common as radiopharmaceu-
ticals. Only one other, 64Cu-PTSM, has really developed much interest. 64Cu-PTSM
has shown limited potential as a hypoxia marker [183], but more promise for the pre-
vention of tumour growth at wound sites following laparoscopic surgery [184], imaging
of immune cell trafficking [185] and neuroimaging of freely moving subjects [186].
Another application of BTS complexes is in studies of myocardial and cerebral
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perfusion (i.e. blood flow at the capillary level), which represent important clinical
applications of nuclear medicine due to the high rates of morbidity and mortality as-
sociated with cardiovascular and cerebrovascular disease [99]. BTS complexes labelled
with 62Cu have been used extensively in perfusion imaging with PET. These uncharged,
lipophilic agents are attractive because they exhibit high first-pass tissue extraction of
tracer, insuring a good correlation between regional concentration of the radiolabel and
the regional rate of tissue perfusion, and prolonged tissue retention. It is anticipated
that 64Cu-labelled BTS complexes will be used in the future as cardiovascular perfusion
markers.
4.3 Targeting tumours with antibodies
Although tracers for metabolism, proliferation, perfusion and hypoxia provide use-
ful imaging of neoplasms, they are relatively non-specific and are usually less useful
for imaging tumours that have very low growth rates. The development of tracers
that target specific tumour antigens is therefore essential for the clinical usefulness
of PET. [187]. Antibodies (Abs) reactive with cancer-associated antigens offer the
prospect of radionuclide targeting at tumours by exploiting the molecular specificity
of the antigen-antibody interaction [188]. Classical biodistribution studies based on
dissecting large numbers of animals and quantifying radiolabelled antibody deposition
provide results in terms of populational averages at specific timepoints, but do not allow
antibody localization to be tracked with respect to time. By contrast, PET imaging
permits three-dimensional determination of radiolabelled antibody distribution in vivo
during the initiation of an autoimmune response, and also the use of fewer animals. For
example, in a study on rheumatoid arthritis dynamic visualisation of a joint-specific
autoimmune response using a 64Cu-labelled antibody showed localisation in diseased
distal joints within minutes of intravenous administration [189]. 64Cu-labelled mon-
oclonal Abs (mAbs) have been used to characterise the internalisation properties of
radioimmunoconjugates in vitro, to obtain their in vivo distributions and to calculate
mouse xenograft dosimetry in preparation for preclinical therapy studies [190].
A number of tetraaza macrocycles have been used for radiocopper labelling of intact
and fragmented Abs. All of them form Cu(II)-complexes of high kinetic stability under
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physiological conditions and this is one of the reasons for the excellent tumour target-
ing ability of radiocopper-labelled Abs [191, 192]. In practise, DOTA is used almost
exclusively and mAb-DOTA conjugates have shown minimal loss of chelated radiocop-
per in vivo. Conjugation of DOTA to mAbs is a simple, water-soluble procedure with
high conjugation efficiency [193].
64Cu-labelled whole Abs are problematic because of their relatively slow clearance
from blood and long biological half-lives leading to images with very high background
signals [187,194]. Efforts have been made in the systematic construction of engineered
antibody fragments with rapid access and high retention in tumorous tissues combined
with excellent clearance properties, although sometimes at the expense of some speci-
ficity [40, 187]. Studies on 64Cu-labelled Ab fragments have revealed suitable in vivo
characteristics for tumour imaging and therapy, but display higher kidney uptake than
intact Abs [195]. One approach to reduce kidney uptake takes advantage of the lysine
specific carboxypeptidase activity of the kidney brush border enzymes that cleave off
the radiolabelled peptide linker from the antibody fragment prior to uptake by prox-
imal tubule cells [196]. Labelling with 64Cu has been used to optimise the design for
specificity of Ab fragments, and demonstrated that engineered diabodies (noncovalent
single chain dimers) have higher tumour retention and higher tumour to blood ratios
than engineered single chains and enzymatically produced fragments [197].
64Cu-DOTA-Ab compounds have been used to quantify and visualise the trafficking
behaviour of tumour-specific T cells to help develop therapeutic protocols [198], and
have potential for in vivo monitoring of apoptosis in humans [199]. They have also
caused complete responses in animal RIT studies at far lower radiation doses than
traditionally prescribed. The intracellular localization of 64Cu may lead to cytotoxic
effects by mechanisms beyond ionizing radiation damage. Elucidation of the unusual
mechanisms of tumour cytotoxicity exerted by 64Cu at low radiation doses offers the
promise of efficacious and minimally toxic RIT agents for cancer patients [200].
One strategy to preserve the pharmacokinetic localisation benefits of intact mAbs is
to separate the delivery of the Ab from that of 64Cu using pretargeting techniques [201].
An unlabelled mAb-receptor construct is first administered and allowed to accumulate
in tumours, then 64Cu is given in the form of a small effector molecule that binds
rapidly with high affinity to the mAb-receptor construct at the tumour site [202]. This
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Figure 4.6: Left: Biodistributions at 2 h after injection of 64Cu-DOTA-biotin in mice
bearing human colorectal carcinoma xenografts pretreated with a mAb-streptavadin
conjugate. Right: Tumour and blood time-activity curves for the same study. Ac-
cumulation of 64Cu-DOTA-biotin in the tumour was extremely rapid: at 5 min post-
injection the tumour-to-blood ratio was already 1.37. Tumour uptake continued to
increase significantly, with consistently high retention. The specificity of binding to
immobilised streptavadin was > 98%. Figures from [202].
approach relies on the tight binding between protein streptavadin (receptor) and B
complex vitamin biotin (effector). Figure 4.6 illustrates an application of the pretar-
geting method.
4.4 Peptides for tumour imaging
As radiolabelled-mAbs are cleaved into smaller fragments to improve biodistribution
they may also loose some of the tumour affinity of the intact mAbs. Peptides, because
of their small size and rapid blood clearance, are an attractive alternative to mAb
fragments [203]. In fact, there has been an exponential growth in the development
of radiolabelled peptides for diagnostic and therapeutic applications in oncology. In
addition to fast clearance, peptides have rapid tissue penetration, low antigenicity
and can be produced easily and inexpensively. However, peptides have problems with
in vivo catabolism, unwanted physiological effects and chelate attachment. The 850
endogenous peptides provide numerous potential probes. For useful applications in
nuclear medicine there is still a lot of work to be done to find the best tracer and
peptide analogue [204]. Some recent developments have met with success (e.g. early
detection of malignant melanomas with a 64Cu-labelled cyclised peptide [205]), and
some with failure (e.g. in vivo instability of a 64Cu-labelled peptide for selective uptake
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by tumours overexpressing matrix metalloproteinases [206]).
Bombesin (BBN) is an amphibian peptide from the skin of the European fire-bellied
toad, Bombina bombina [203]. It is an analogue of human gastrin-releasing peptide
(GRP) and binds to the GRP receptor with high affinity and specificity. The GRP
receptor is overexpressed in several neuroendocrine tumours, including prostate cancer.
64Cu-DOTA-BBN compounds have been investigated for cancer, typically prostate
adenocarcinoma, diagnosis and therapy [207–210]. Clear delineation of such tumours
has been achieved, but there are still concerns regarding dosimetry, GRP receptor
saturation in small animal studies, the influence of blood flow, and washout [211].
The peptide somatostatin is involved in the regulation and release of a number of
hormones, and somatostatin receptors are expressed in a large number of human tu-
mours. Targeting such receptors has been a goal in cancer treatment for a long time,
and somatostatin analogues that have longer biological half-lives have been developed
to achieve longer residence times. One such analogue, octreotide (OC), continues to be
used extensively in 64Cu radiopharmacy [212]. DOTA, TETA and TE2A are the cur-
rently preferred bifunctional ligands because of their in vivo stabilities. Recent studies
of 64Cu-labelled OC show high affinity for somatostatin receptors both in vitro and in
vivo, good kidney clearance and relatively low liver accumulation. Target specificity,
typically to neuroendocrine tumours, is controlled by modifications to the chelator or
to OC [213–219], or to potentially use gene transfer methods to upregulate tumour-
associated receptor expression [220].
Integrins are hetorodimeric receptors consisting of one α- and one β-subunit. They
mediate cell adhesion to the extracellular matrix or between cells, and several αβ in-
tegrins are involved in cancer metastasis and angiogenesis. Some of them recognise
the arginineglycineaspartic acid (RGD) peptide sequence, and so they have been eval-
uated as treatment of cancer or as inhibitors of angiogenesis [221]. 64Cu-TETA has
been linked to collagen fragments to try to target α3β1 integrins [222]. More success-
ful has been the targeting of αvβ3 integrin expression with bitistatin or RGD pep-
tides [223–227]. Target specificity can be improved by pegylating the RGD peptides or
by forming dimeric or tetrameric RGD peptides. Figure 4.7 illustrates a 64Cu-DOTA-
tetrameric RGD peptide application.
One of the latest diagnostic strategies utilising 64Cu-labelled peptides has been the
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Figure 4.7: (A) Decay-corrected whole-body µPET images with good tumour contrast
of mice bearing human glioma xenografts at times after injections with 64Cu-DOTA-
tetrameric RGD peptide. (B) Time-activity curves showing high tumour uptake and
low tumour washout. (C) Intergrin specificity demonstrated by comparing tumour
uptake in mice with (upper) or without (lower) excess non-labelled tetrameric RGD
peptide. Figure taken from [226].
imaging of KRAS mRNA in human pancreatic cancer xenografts using chelator-PNA-
peptide chimeras. 90% of patients with pancreatic cancer carry activating mutations
in their KRAS oncogenes. Oncogene-targeted oligonucleotide sequences specifically
downregulate KRAS, thus inhibiting cancer cell proliferation. Overexpressed or mu-
tated KRAS mRNAs are significant markers of oncogenic transformation that could
by used to identify cancerous masses by PET [228, 229]. PET imaging of oncogene
expression using a 64Cu-vascoactive intestinal peptide analogue has shown significantly
greater uptake in breast cancer xenografts compared to the equivalent 99mTc-labelled
analogue [230]. And the potential of 64Cu-labelled antigene and antisense PNAs is
under evaluation as specific molecular probes for the early detection of cancer and
ultimately for patient specific radiotherapy [231].
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4.5 Nanoparticles for drug development
PET has enormous potential for improving the efficiency of the drug development
process and the clinical use of targeted drugs [232]. In cancer drug development, the
goals in molecular imaging are to aid the in vivo definition of target specificity, to
facilitate rapid characterization of pharmacokinetic and pharmacodynamic properties
of candidate drugs, and to visualize the effects of therapeutic molecules on target
biological processes [233].
Earlier three main methods were used for tumour targeting with radiopharma-
ceuticals: metabolic, transport and receptor-mediated processes [234]. Now, intra-
venously administered nanoparticles for drug delivery and imaging of tumours and
other malignancies is seen as very promising, and its development has been a major
challenge [235]. Attention has focused recently on the design and synthesis of poly-
mer nanostructures called shell cross-linked nanoparticles (SCKs). They constitute a
unique class of materials with amphiphilic core-shell morphology, and are prepared by
intramicellar crosslinking of polymer chains located within the shell domain of polymer
micelles [236]. They are characterised by their structural integrity and available func-
tionality to attach receptor-recognising or receptor-specific ligands on the shell surface.
These nanoparticles are also capable of hydrophobic guest sequestration and transport,
and SCKs with positively-charged surface functional groups have been shown to pack-
age DNA. Attachment of a HIV protein transduction domain peptide sequence to the
SCK shell facilitates intracellular delivery of the nanoparticles. The control over size,
shape, and composition of these nanoparticles suggests that SCKs may be suitable
nanoscale carriers for the transport and delivery of biologically active agents.
Both biodistribution studies and µPET imaging are used to evaluate the fate of
64Cu-labelled SCKs in vivo, focusing on blood retention and accumulation in the main
excretory organs (liver, spleen, kidney and lungs). Longevity in the bloodstream is a
highly demanded feature for a drug delivery system, giving the carriers enough time
to reach their targets and to release their cargo in a continuous and controlled fash-
ion. To avoid rapid blood clearance, administered particles must retard opsonization
and macrophage recognition which results in sequestration by organs of the reticuloen-
dothelial system (RES), such as the liver and spleen. Furthermore, injected particles
and their aggregates should be small and deformable enough to avoid filtration through
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Figure 4.8: Dual-tracer autoradiographs demonstrating regional concentration of 64Cu-
labelled folate-conjugated SCKs and 18F-FDG in mice bearing human nasopharyngeal
epidermal carcinoma xenografts. Sizeable zones appear that display no accumulation
of either FDG or nanoparticles and that reasonably correspond to necrotic areas. How-
ever, despite the general concordance of regional 18F and 64Cu accumulation within the
tumour, some areas exhibit accumulation of only one radiotracer due to the different
accumulation mechanisms. FDG is a small molecule that diffuses into tumour tissues
and accumulates in areas of high metabolic activity, whereas SKCs extravasate from
hyperpermeable blood vessels and concentrate in vascularized tumour tissues regardless
of tumour biochemistry. Figure taken from [235].
the lung capillary bed and the splenic interendothelial cell slits [237].
An example study evaluated 64Cu-labelled folate-conjugated SCKs as candidate
agents to shuttle radionuclides and drugs into tumours overexpressing the folate recep-
tor (FR) (Figures 4.8 and 4.9) [235]. Despite high RES uptake, the evaluated 64Cu-
labelled SCKs exhibited long circulation in blood and were able to passively accumulate
in tumours. SCK-folate uptake was competitively blocked by excess folate in small-
size solid tumours, suggesting interaction with the FR. Earlier reported radiocopper-
labelled folate conjugates have met with less success: 67Cu-bis(N4-methythiosemicarbazone)-
folate and 67Cu-cyclam-folate. Xenograft KB tumour localisation by the former was
unaffected by co-administration of excess folate acid, and similarly renal uptake was
unaffected for the latter [238]. For these reasons, functionalized SCKs are promising
drug-delivery agents for imaging and therapy of early-stage solid tumours.
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Figure 4.9: Synthesis of 64Cu-labelled folate-conjugated SCK. (i)-(ii) The micelle is
prepared from the diblock copolymer poly(acrylic acid-b-methyl acrylate) followed by
intramicellar crosslinking to produce a shell cross-linked nanoparticles. (iii) A folate-
PEG1,600-amine is conjugated onto the shell surface of the SCK by activating a portion
of the available carboxylic acids with a methiodide. (v) The carboxylic groups on
the SCK-folate shell are activated by adding N-hydroxysulfosuccinimide sodium salt
and centrifugally filterd. The activated esters are functionalized with TETA-NH2.
64Cu-acetate is added to the TETA-SCK solutions and incubated at for 2.5 h in a
thermomixer. After incubation, diethylenetriaminepentaacetic acid is added and the
mixture incubated for 10 min at room temperature. Radiochemical purity of the 64Cu-
labeled SCK is determined by thin-layer chromatography. The labelling yield is > 95%.
Figure taken from [235].
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Chapter 5
Conclusions
Positron-emitting 64Cu will not replace the extremely versatile 11C, 13N, 15O and 18F
widely employed in current PET radiopharmacy. However, the radioactive decay prop-
erties of 64Cu, along with the ability to exploit unique aspects of copper chemistry,
does make it attractive for preclinical and clinical PET applications [99].
It is worth comparing the realistic yields and purities of 64Cu produced from the
two most common routes, 64Zn(n,p) and 64Ni(p,n). The reactor production yields 600
MBq/h per g of natZn and the 67Cu impurity is 0.1% at EOB. The (p,n) process yields
typically 236 MBq/µAh and level of major impurity 61Cu is 0.41%. Apparently the
yield of the reactor production is higher than the (p,n) process, but it is not so in reality.
The cumulative yield of the reactor production for 24 h irradiation is 8.5 GBq/g Zn,
whereas the yield for a 5 h irradiation with 30 µA protons (energy 12→9 MeV) on
enriched 64Ni is 35 GBq. Therefore, the (p,n) process has the advantage that a low
energy cyclotron is adequate for production purposes with significantly higher yields
as compared to the reactor production [78].
Electroplating a sufficiently thick layer of enriched 64Ni onto a gold substrate is still
a challenge for some groups. This step will need to be improved for reliable use in
routine production. Pulse layering is currently the more efficient technique. Heat flow
simulations of Au(Ni) accelerator targets under intense ion beams would be useful to
evaluate the relative power tolerance of grazing targets and gas-cooled, perpendicular
targets, and to aid target design optimization. It is possible to separate 64Cu at the
required purities from irradiated nickel by anion exchange chromatography within 3
h. This is very important for the utilization of 64Cu in experimental and/or clinical
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application.
64Cu is utilised in a wide range of biological tracer studies, but experiments are lo-
calised to only those centres that already have routine 64Cu production. Bis(thiosemi-
carbazone) 64Cu-ATSM exhibits selectivity for hypoxic tumour tissue and may provide
a successful diagnostic and therapeutic modality for tumour ischaemia. Labelling of
antibodies and peptides will most likely continue to grow, although mostly at the pre-
clinical small-animal stage. Already five 64Cu-labelled radiopharmaceitucal compounds
are listed in the Molecular Imaging and Contrast Agent Database [239] thus conferring
some degree conventionality. If RES uptake issues can be solved, then biodistribution
studies, autoradiography and PET imaging of 64Cu-labelled shell cross-linked nanopar-
ticles are potentially very important developments that could accelerate preclinical drug
evaluation.
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